Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- S-4 Registration of securities issued in business combination transactions
- 3.5 Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc
- 3.6 Bylaws of Oruka Therapeutics, Inc, As Currently In Effect
- 4.3 Investor Rights Agreement, Dated March 6, 2024, by and Among Oruka Therapeutics, Inc. and Certain Parties Thereto
- 10.40 Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.41 Form of Restricted Stock Notice and Restricted Stock Purchase Agreement of Oruka Therapeutics, Inc
- 10.42 Form of Stock Option Agreement Under Oruka Therapeutics, Inc. 2024 Equity Incentive Plan
- 10.43 Amended and Restated Director Offer Letter, Dated March 22, 2024, Between Oruka Therapeutics, Inc. and Samarth Kulkarni
- 10.44 Director Offer Letter, Dated April 24, 2024, Between Oruka Therapeutics, Inc. and Kristine Ball
- 10.45 Form of Indemnification Agreement Between Oruka Therapeutics, Inc. and Its Directors and Officers
- 10.46 Amended and Restated Employment Offer Letter, Dated February 14, 2024, by and Between Oruka Therapeutics, Inc. and Lawrence Klein
- 10.47 Amended and Restated Employment Offer Letter, Dated March 11, 2024, by and Between Oruka Therapeutics, Inc. and Arjun Agarwal
- 10.48 Amended and Restated Employment Offer Letter, Dated March 15, 2024, by and Between Oruka Therapeutics, Inc. and Joana Goncalves
- 10.49 Amended and Restated Employment Offer Letter, Dated April 12, 2024, by and Between Oruka Therapeutics, Inc. and Paul Quinlan
- 21.1 List of Subsidiaries of Arca Biopharma, Inc
- 23.1 Consent of KPMG LLP, Independent Registered Public Accounting Firm of Arca Biopharma, Inc
- 23.2 Consent of Pricewaterhousecoopers LLP, Independent Registered Public Accounting Firm of Oruka Therapeutics, Inc
- 99.5 Consent of Lucid Capital Markets, LLC
- 99.6 Consent of Lawrence Klein to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.7 Consent of Kristine Ball to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.8 Consent of Carl Dambkowski to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.9 Consent of Peter Harwin to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.10 Consent of Samarth Kulkarni to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- 99.11 Consent of Cameron Turtle to Serve As a Director of Arca Biopharma, Inc., to Be Renamed Oruka Therapeutics, Inc
- EX-FILING FEES Filing Fee Table
- Download Excel data file
- View Excel data file
Associated filings
- 1 Aug 24 424B3 Prospectus supplement
- 25 Jul 24 EFFECT Notice of effectiveness
- 22 Jul 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 9 Jul 24 S-4/A Registration of securities issued in business combination transactions (amended)
- 18 Jun 24 S-4/A Registration of securities issued in business combination transactions (amended)
-
13 May 24 S-4 Registration of securities issued in business combination transactions
ORKA similar filings
- 22 Jul 24 Registration of securities issued in business combination transactions (amended)
- 9 Jul 24 Registration of securities issued in business combination transactions (amended)
- 18 Jun 24 Registration of securities issued in business combination transactions (amended)
- 13 May 24 Registration of securities issued in business combination transactions
- 24 Nov 08 Registration of securities issued in business combination transactions (amended)
- 30 Oct 08 Registration of securities issued in business combination transactions
- 13 Dec 02 Registration of securities issued in business combination transactions (amended)
Filing view
External links